Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 59Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Head and Neck Neoplasms 6Neoplasms, Squamous Cell 3Neoplasm Metastasis 2Colorectal Cancer Metastatic 2Carcinoma, Squamous Cell 2Upper Gingival Squamous Cell Carcinoma 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Intestinal Neoplasms 1Deglutition Disorders 1Colonic Neoplasms 1Carcinoma 1Acne Vulgaris 1

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 58Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Drug Therapy 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4Palliative Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasms × Cetuximab × Clear all
NCT01134666 2017-06-09

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Merck KGaA, Darmstadt, Germany

Terminated
165 enrolled
Gastrointestinal

Intestinal Neoplasms, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡